<DOC>
	<DOC>NCT01022983</DOC>
	<brief_summary>The purpose of this study is to investigate the safety and efficacy of Levosimendan given preoperative to patients with heart failure undergoing noncardiac surgery.</brief_summary>
	<brief_title>Preoperative Levosimendan and Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Hip Fractures</mesh_term>
	<mesh_term>Simendan</mesh_term>
	<criteria>Acute surgery. Hip Fracture Patient with cardiac failure (EF &lt; 35%) or known coronary disease At least 2 of 11 comorbidities Patient has to use at least one heart failure medication Symptoms of heart failure NTproBNP &gt; 2000pg/ml &lt; 18 years old Participants in other pharmacological study Abuse of medicaments or alcohol Pregnant or breastfeeding women AMI at admission HOCM Serious aortic stenosis (&lt; 1 cm2) Sustained ventricular tachycardia Earlier episodes of "torsades de pointes" Sustained heartbeat &gt; 120/minute Systolic BP &lt; 90 mmHg Surgery planned not before 2 hours of study medication can be infused preoperative Cardiac surgery Dementia SK &lt; 3 mmol/l Allergy levosimendan Serious liver failure (Known Class C ChildPugh score) Serious kidney failure (GFR &lt; 30 ml/min.) Prolonged QTcinterval (male QTc &gt; 0,43 s, female QTc &gt; 0,45 s)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>